Trial Profile

A Phase 2, Open-Label Study of Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Transformed Marginal Zone Lymphoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Carboplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Rituximab (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use

23 Aug 2022 Status changed from active, no longer recruiting to discontinued.
25 Oct 2021 Planned End Date changed from 1 Sep 2023 to 1 Jun 2023.
25 Oct 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com